Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ISIS Pharmaceuticals, Inc. : ISIS, YHOO, MU and INTC added to Nasdaq Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2013 | 03:05pm CEST

New York, NY -- (ACCESSWIRE) --06/25/2013-- Equity Profile Report initiates a NASDAQ Active Stock Watch List adding Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), Yahoo! Inc. (NASDAQ:YHOO), Micron Technology Inc. (NASDAQ:MU) and Intel Corporation (NASDAQ:INTC)

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) a leading company in antisense drug discovery and development finished their previous session (+29.24%) on 9,784,879 shares traded. They recently announced that the data they received from the PHASE 2 study of ISIS-APOCIIIRx in patients with high triglycerides and type 2 diabetes was very positive. They are currently us (+275.93%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Isis Pharmaceuticals, Inc. (NASDAQ:ISIS)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=ISIS&SubId=AW

Yahoo! Inc. (NASDAQ:YHOO) ?a company that provides search, content and communication tools via the web and mobile devices around the world finished their previous session (-4.47%) on 37,007,539. They recently announced that they have completed their acquisition of Tumblr, who are one of the fastest growing media networks in the world. This acquisition is expected to grow Yahoo?s audience by more than one billion monthly visitors. This news has prompted Equity Profile Report to add Yahoo! Inc. (NASDAQ:YHOO) to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Yahoo! Inc. (NASDAQ:YHOO)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=YHOO&SubId=AW

Also mentioned in Equity Profile Report?s Active Stock Watch List and Investor Poll was: Micron Technology Inc. (NASDAQ:MU), Intel Corporation (NASDAQ:INTC), ARM Holdings plc (NASDAQ:ARMH) and NetApp, Inc. (NASDAQ:NTAP)

To see what other investors are saying about: MU, INTC, ARMH and NTAP

Click here: http://www.equityprofilereport.com/PR.aspx?stock=MU-INTC-ARMH-NTAP&SubId=AW

EquityProfileReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals EquityProfileReport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:http://www.EquityProfileReport.com

Disclosure: EquityProfileReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit EquityProfileReport.com website, for complete risks and disclosures.

Contact Info:

Equity Profile Report
editor@EquityProfileReport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ISIS PHARMACEUTICALS, INC.
01:01p WEBCAST ALERT : Ionis Pharmaceuticals' Second Quarter 2016 Financial Results Con..
07/19 IONIS PHARMACEUTICALS : Licenses First Oral Antisense Drug Acting Locally in the..
07/17 STATE STREET : Increases Stake in Ionis Pharmaceuticals Inc.
07/12 IONIS PHARMACEUTICALS : Announces Publication in Nature Biotechnology of a Novel..
07/07 IONIS PHARMACEUTICALS : Reports Positive Clinical Data on IONIS-TTR Rx at the XV..
06/29 IONIS PHARMACEUTICALS : Akcea Therapeutics Announces Launch of IN-FOCUS, a Resea..
06/27 IONIS PHARMACEUTICALS : Akcea Announces Publication of Positive Volanesorsen Cli..
06/22 IONIS PHARMACEUTICALS : to Host R&D Day
06/16 IONIS PHARMACEUTICALS : Novel imaging model helps reveal new therapeutic target ..
06/08DJJudge Sides With Gilead in Drug-Patent Dispute -- WSJ
More news
Sector news : Biotechnology & Medical Research - NEC
12:45a GILEAD SCIENCES : cuts 2016 sales forecast, cites hepatitis C drugs
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 2nd Update
07/25DJCELGENE : Drug Misses Secondary Endpoint in One of Its Lymphoma Trials
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 3rd Update
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Financials ($)
Sales 2016 238 M
EBIT 2016 -154 M
Net income 2016 -187 M
Finance 2016 134 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 13,8x
EV / Sales 2017 11,4x
Capitalization 3 428 M
More Financials
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 12
Average target price 32,4 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & SVP-Finance
C. Frank Bennett Senior Vice President-Antisense Research
Joseph H. Wender Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%3 428
INCYTE CORPORATION-20.30%16 216
CELLTRION, INC.--.--%10 681
LONZA GROUP AG11.40%9 730
QUINTILES TRANSNATIONA..7.89%8 865
ALKERMES PLC-36.86%7 576
More Results